The aim of this study was therefore to evaluate the ROCKI and ROCKII activation status in different tumor types of breast cancer, including carcinoma in situ (CIS), invasive carcinoma (IC) and invasive carcinoma with metastasis (ICM), by immunohistochemical staining with anti-pS1333 ROCKI and anti-pS1366 ROCKII antibodies. The gene discussed is ROCK2; the disease is in situ carcinoma.